explore -WSS

explore

author：hotspot 2025-09-04 02:34:25 - browse：6

Seng Cheng has been working in gene therapy for nearly as long as gene therapy has been a field. As a young scientist in the early 1990s, he was part of one of three teams racing to develop a gene therapy for cystic fibrosis, a high-profile effort that resulted in national headlines, prestigious publications, and zero patients cured.

So he’s seen the field’s highs and lows. Lately, there have been a lot of both, including at Pfizer, the company Cheng called home until this summer. The pharma brought three potentially powerful gene therapies for muscular dystrophy and hemophilia into late-stage trials but, in January, chose to abandon a large portfolio of early stage candidates that relied on the same technology: adeno-associated viruses, or AAVs, a group of small bugs that scientists spent two decades taming into a gene shipping system.

The move seemed emblematic. Across the industry, AAV companies have been struggling, either shelving programs or stopping work altogether, while investors shuttled money toward new technologies such as CRISPR and its various permutations. Longtime researchers feared promising drugs, particularly for ultra-rare diseases, might get lost in the shuffle.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： The Affordable Care Act has saved billions in health care costs

Wikipedia

knowledge

WSS

Why Medicare shouldn’t cover every FDA

Asbestos, a deadly carcinogen, banned by EPA

Neuroscience’s long legacy of racism

Virtual Event: March of the Biosimilars

Methadone treatment changes are coming. Do they go far enough?

Philips to halt sales of sleep apnea machines in U.S.

entertainment

explore

focus

Alkermes shareholders re

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

How one medical school became remarkably diverse

AstraZeneca to buy developer of next

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

White House pharmacy plagued with problems, investigation finds

Moonlake's readout produced a cash windfall. Risks remain

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

After affirmative action ruling, medical educators look to 'holistic review'

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

knowledge

Bernie Sanders is gearing up to subpoena pharma CEOs

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

The Affordable Care Act has saved billions in health care costs

Syphilis numbers in the United States reach record heights

Colonoscopy prep: Liquid

Pancreatic cancer early detection could be helped by AI

Wikipedia

knowledge

knowledge

hotspot